While Novo Nordisk’s blockbuster weight loss drug WeGovy has caught repeated flack for its purportedly high price tag, the drug manufacturer revealed new data Tuesday alleging that WeGovy is more affordable to insured Americans than the public may think.
According to Novo Nordisk, approximately 80% of U.S. patients with health insurance only pay $25 per month for their mensual supply of WeGovy.
The company went on to say that more and more employers are opting in to add WeGovy coverage for their employees.
Meanwhile, the list price for a full month of WeGovy sits at $1,350.
